Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.